Seven-Year clinical outcomes after implantation of Eyecryl posterior chamber phakic intraocular lenses for high myopia


KIRGIZ A., Yalçınkaya Çakır G., Çakır İ., Yıldırım Y., Ağca A.

European Journal of Ophthalmology, cilt.34, sa.5, ss.1424-1431, 2024 (SCI-Expanded, Scopus)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 34 Sayı: 5
  • Basım Tarihi: 2024
  • Doi Numarası: 10.1177/11206721241229311
  • Dergi Adı: European Journal of Ophthalmology
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.1424-1431
  • Anahtar Kelimeler: IOLs < LENS / CATARACT, refractive phakic IOLs < REFRACTIVE SURGERY, postoperative posterior segment / vitreous problems < LENS / CATARACT, specular microscopy < LENS / CATARACT, complications of refractive surgery < REFRACTIVE SURGERY
  • Sağlık Bilimleri Üniversitesi Adresli: Evet

Özet

Purpose: To evaluate the long-term clinical outcomes, safety and efficacy of Eyecryl posterior-chamber phakic intraocular lens implantation (pIOL) implantation in patients with high myopia. Methods: Patients with myopia between −6.00 and −20.00 dioptres and with endothelial cell density (ECD) was ≥2300 cells/mm2 were included. Preoperative and postoperative first, fourth, and seventh years of refraction, uncorrected/corrected distance visual acuity (UDVA/CDVA), ECD, central vault were detected. Results: Thirty-six eyes were analyzed. The mean UDVA and CDVA in postoperative seventh years were 0.25 ± 0.31 and 0.13 ± 0.24 logMAR, respectively. The safety and efficacy indices were 1.55 ± 0.54 and 1.24 ± 0.53, respectively. The mean cumulative ECD loss was 6.96% (p < 0.001). The central vault at the 1st and the 7th year were 0.52 ± 0.14 and 0.49 ± 0.14 mm, respectively (p = 0.25). Conclusions: These findings supported the long-term stability, efficacy, safety of the Eyecryl pIOL for high myopia. Eyecryl posterior chamber pIOL is one of the effective refractive options in correcting high myopia.